And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is quickly filling up. Besides the usual promenading with the official mascot, we plan to hang with at least two of our short people, one of whom returns from an institution of higher learning. We are also readying another listening party with Mrs. Pharmalot (the rotation will include this, this and this) and will stop to observe some ancient rituals (sufganiyot, anyone?). And what about you? Holidays are nearing, but there is still time to squeeze in a visit to a nearby temple of consumption. You could also plan a much-needed getaway. Or work on your list of resolutions for the next year — if so, we wish you much luck. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon….
AbbVie is leaving several major industry groups representing its interests in Washington, D.C., STAT reports. The company is leaving the Pharmaceutical Research and Manufacturers of America and the Biotechnology Innovation Organization, the two prominent pharmaceutical trade associations, according to the groups. AbbVie is also leaving the Business Roundtable, a group comprising the chief executives of the largest U.S. companies. The decision comes as regulators begin to implement the drug-pricing provisions of the Inflation Reduction Act that drugmakers spent millions in lobbying to defeat.
India told the World Health Organization that samples taken from Maiden Pharma, whose products were linked to the deaths of 69 children in Gambia, complied with required specifications, Reuters writes. Indian authorities ordered a production halt at a Maiden Pharmaceuticals factory in Sonepat, India, in October after a World Health Organization report said Maiden cough and cold syrups might be linked to the deaths. In a Dec. 13 letter to the WHO, India’s drugs controller general said that tests on samples of Maiden Pharma products “have been found to be complying with specifications” and showed the samples were not contaminated with ethylene glycol and diethylene glycol. Maiden plans to re-open the plant, Reuters adds.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect